Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IRB Reform Is Low-Hanging Fruit For FDA-Duke Clinical Trial Initiative

This article was originally published in The Gray Sheet

Executive Summary

One of the first jobs for a new FDA/Duke University partnership aimed at modernizing clinical trials will be reforming policies for institutional review boards so studies can get off the ground more quickly, participants say

You may also be interested in...



FDA Nominee Califf Seeks Clinical Trial, Combo Product Reforms

President Obama nominated Robert Califf for FDA commissioner, and Senate HELP Chairman Lamar Alexander said the committee "will move promptly" to consider the nomination. If confirmed, he would be expected to lead reforms of the combination products review process, among other initiatives. However, while the initial positive response from Sen. Alexander suggests the possibility of a smooth confirmation, it certainly isn't guaranteed.

Hamburg’s Departure Hinged On Selection Of FDA Leadership Team

Medical countermeasures expert Luciana Borio moves to chief scientist role; Hamburg offers preview of the leadership approaches of Stephen Ostroff and Robert Califf.

Duke's Califf Tapped For FDA Deputy Post; Some See Succession Planning

Robert Califf will join FDA in February as deputy commissioner for medical products and tobacco. He may be being groomed to become the next commissioner, agency watchers suggest.

Related Content

UsernamePublicRestriction

Register

MT025571

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel